Bitcoin Core revealed a medium-severity vulnerability (CVE-2025-62859) that could cause nodes to repeatedly delay block processing by 10 minutes per failed request. The flaw affected versions before Bitcoin Core 29.2 and 30.0, allowing a malicious peer to manipulate witness data and trigger repeated timeouts if the node failed validation. This could indefinitely delay block downloads, especially if the attacker controlled all high-bandwidth peers or the node ran with the -blocksonly option. The issue was responsibly disclosed by Eugene Siegel and has been fixed in recent Bitcoin Core updates.
Bitcoin Core's disclosed vulnerability comes as 27 of 50 major cryptocurrencies on Pluang rose while 22 fell, as of Nov 12, 2026 05:22 WIB. Among these, Filecoin (FIL) gained 2.97% to Rp13.938 with 100% buy order activity, Stellar (XLM) rose 2.90% to Rp2.699 with 95% buy orders, and Uniswap (UNI) dropped 3.70% to Rp117.501 with 75% sell orders. This snapshot provides a sector-level market context for readers following Bitcoin Core news.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
